Evidence map›Paper›PMID 41573936›Full record

ArticlebioRxiv : the preprint server for biology2026

T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells.

Matthias Obenaus, Clara L Poupault, Christopher S McGinnis, Céline Prange, Hua Jiang, Leon L Su, Xiaojing Chen, Zhuang Miao, Joseph J Muldoon, Winnie Yao and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Matthias ObenausDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.
Clara L PoupaultDepartment of Pediatrics, Stanford University; Stanford, CA, USA.
Christopher S McGinnisDepartment of Pathology, Stanford University; Stanford, CA, USA.ORCID 0000-0001-6923-9341
Céline PrangeDepartment of Bioengineering, Stanford University; Stanford, CA, USA.
Hua JiangDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.
Leon L SuDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.
Xiaojing ChenDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.
Zhuang MiaoDepartment of Pathology, Stanford University; Stanford, CA, USA.
Joseph J MuldoonDepartment of Medicine, UC San Francisco; San Francisco, CA, USA.
Winnie YaoDepartment of Pathology, Stanford University; Stanford, CA, USA.
Deepa WaghrayDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.
Qinli SunDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.
Justin EyquemDepartment of Medicine, UC San Francisco; San Francisco, CA, USA.
Rogelio A Hernández-LópezDepartment of Genetics, Stanford University; Stanford, CA, USA.
Ansuman T SatpathyDepartment of Pathology, Stanford University; Stanford, CA, USA.
Julien SageDepartment of Pediatrics, Stanford University; Stanford, CA, USA.
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University; Stanford, CA, USA.ORCID 0000-0001-9273-0278

Funding

Structure-based engineering of immune cytokine signalingR01AI051321 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2002 to 2026
$5.6M
Interrogating Immunomodulation for Anti-Metastatic TherapyK99CA293137 · NCI · STANFORD UNIVERSITY · PI Christopher Swart McGinnis · 2025 to 2026
$226k
NCI NIH HHS K99 CA293137NIAID NIH HHS R01 AI051321
6 · The paper itself

Abstract

Bispecific T cell engagers (TCEs) often exhibit limited efficacy in solid tumors, in part due to immunosuppressive cues in the tumor microenvironment and low expression of targetable tumor antigens. Therapeutic strategies to improve TCE target sensitivity and enhance T cell effector functions therefore have significant translational potential. Here, we engineered TCEs that induce T cell activation

Identifiers

PMID41573936
PMCPMC12822708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.